BASIC FACTS
DATE OF LAUNCH
12 NOVEMBER 2015
CATEGORY
EQUITY
TYPE
ELSS
AUM*
Rs.388 Crore
BENCHMARK
NIFTY 500 TOTAL
RETURN INDEX
WHAT IT COSTS
NAV**
GROWTH OPTION
Rs 22.2
IDCW
Rs 15.18
MINIMUM INVESTMENT
Rs 500
MINIMUM SIP AMOUNT
Rs 500
EXPENSE RATIO*** (%)
2.53
EXIT LOAD: 0
**AS ON 7 JUNE 2022
*AS ON 30 APRIL 2022
***AS ON 30 APRIL 2022
FUND MANAGER
SRINIVAS RAO RAVURI
TENURE: 2 YEARS, 8 MONTHS
Recent portfolio changes
New Entrants: Bayer CropScience,
Co. .
Complete Exits: Mahindra & Mahindra, .
Increasing allocation: Aurobindo Pharma, , , , Dr. Reddy’s Laboratories, , , , The .
Should you buy?
Earlier known as PGIM India Long Term Equity, this fund takes a large-cap tilt like many of its peers. The rest is spread across mid- and small-caps. It runs a compact portfolio of less than 40 stocks, taking large positions in its top few bets. The fund prefers quality businesses with high ROCE and ROE, operating as a leader or competitive challenger in its space with clear visibility of earnings for the next 3-5 years. The fund has built a decent track record in a short span of time, with an ability to cushion against the market downside that is better than many of its peers. The presence of a skilled fund manager at its helm provides added comfort.
(Source: Value Research)